Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Abgenix cleared to become sole owner of XenoMouse technology

Dec. 28, 1999

Bayer allies with MorphoSys to accelerate drug discovery

Dec. 28, 1999

Transkaryotic Therapies achieves milestone in Aventis collaboration

Dec. 23, 1999

Cambridge NeuroScience issued two patents, three patent allowances

Dec. 23, 1999

Aurora Biosciences announces two ion channel technology agreements

Dec. 23, 1999

Two new patents issued to Helix for drug delivery technology

Dec. 22, 1999

Immune Response acquires T-cell receptor technology from Connetics and Xoma

Dec. 16, 1999

Lexicon Genetics to provide knockout mice for BASF

Dec. 16, 1999

The Rockefeller University designs inhibitors of enzyme involved in melatonin biosynthesis

Dec. 15, 1999

Abgenix and CuraGen to develop genomics-based human antibody drugs

Dec. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...